Bavarian Nordic A/S BAVA.CO · DKK

Its shares trade on Nasdaq Copenhagen under the ticker BAVA.CO. It has been listed since 2 November 1998. In the fiscal year to 31 December 2025, it reported revenue of DKK 6.17bn and net income of DKK 1.38bn. At that date it held total assets of DKK 14.95bn and shareholders' equity of DKK 12.87bn.

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Luc DebruyneIndependent Chairman of the BoardDKK 1.7m
• Dr. Paul ChaplinPresident, Chief Executive Officer, since 2014DKK 34.2m
• Ms. Anne EberhardIndependent Deputy Chairman of the BoardDKK 855,000
• Mr. Henrik JuuelExecutive Vice President, Chief Financial OfficerDKK 16.2m
• Mr. Russell ThirskExecutive Vice President, Chief Operating Officer
• Mr. Jean-Christophe MayExecutive Vice President, Chief Commercial Officer
• Ms. Linette AndersenDirector, Employee ElectedDKK 470,000
• Mr. Thomas BennekovDirector, Employee ElectedDKK 470,000
• Ms. Anja GjolDirector, Employee ElectedDKK 470,000
• Ms. Karen JensenDirector, Employee ElectedDKK 470,000
• Ms. Heidi HunterIndependent DirectorDKK 765,000
• Ms. Montse MontanerIndependent DirectorDKK 565,000

Overall

73

Environment

84

Social

79

Governance

57

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.